Parkinson's disease 'jerking' side effect detected by algorithm

January 8, 2018, Heriot-Watt University
Credit: Heriot-Watt University

A mathematical algorithm that can reliably detect dyskinesia, the side effect from Parkinson's treatment that causes involuntary jerking movements and muscle spasms, could hold the key to improving treatment and for patients with the disease.

Scientists in Heriot-Watt's School of Mathematical and Computing Sciences have conducted clinical studies that prove their algorithm reliably detects , an unexplained side effect of Parkinson's disease. They are working to develop a new home monitoring device for patients that will help their clinician adapt and improve treatment.

The motor features of Parkinson's disease, such as tremor, postural instability, and a general slowing of movement, are caused by a lack of dopamine, and treat this through dopamine replacement drugs such as levodopa.

Dr. Michael Lones, leader of Heriot-Watt's Complex Systems Laboratory, said: "The problem is that, as Parkinson's disease worsens over time, the dose required to treat the motor features increases, which increases the risk of inducing dyskinesia or making it more prolonged and severe.

"Patients don't see their clinicians that frequently, and medication only changes at regular review periods. So it's very difficult for clinicians to know when dyskinesia is occuring.

"A better solution would be a portable device that identifies and monitors dyskinesia while patients are at home and going about day-to-day life, broadcasting data to their clinicians through simple mobile technology."

Dr. Lones and his team carried out two clinical studies, with 23 Parkinson's disease patients who had all displayed evidence of dyskinesia. Lightweight sensing modules were fitted to each patient's legs, arms, torso, head and trunk using adjustable bands, and patients had their movements measured each hour using the MDS Unified Parkinson's Rating Scale (MDS-UPDRS). An infrared camera was used to film patients as they moved around and footage was later marked up by three trained clinicians who graded the intensity of dyskinesia exhibited by patients.

Dr. Lones said: "The allowed us to capture and mine data about how move and used those to build models.

"We developed our algorithm to make as few assumptions as possible. With traditional analysis, you make assumptions about what a looks like. If it doesn't look like exactly that way, you won't detect it. Very little is known about dyskinesia, so we wanted the algorithm to be as 'open' as possible.

"The works by building a mathematical equation that describes patterns of acceleration which are characteristic of dyskinesia. The system then uses this equation to discriminate periods of dyskinesia from other movements, relaying this information to clinicians who can then adapt a patient's medication as necessary."

Explore further: 1st drug for tardive dyskinesia approved

More information: Michael A. Lones et al. A New Evolutionary Algorithm-Based Home Monitoring Device for Parkinson's Dyskinesia, Journal of Medical Systems (2017). DOI: 10.1007/s10916-017-0811-7

Related Stories

1st drug for tardive dyskinesia approved

April 12, 2017
(HealthDay)—Ingrezza (valbenazine), the first drug to treat adults with the neurological disorder tardive dyskinesia, has been approved by the U.S. Food and Drug Administration.

New medication significantly decreases involuntary movement

April 7, 2017
Antipsychotic treatment can cause involuntary movements such as lip smacking, tongue protrusions and excessive eye blinking. These movements typically occur after more than 3 months of treatment and are called tardive dyskinesia.

Investigational drug may reduce involuntary movements

April 12, 2011
Results of the first randomized, placebo-controlled long-term clinical trial show the investigational drug safinamide may reduce dyskinesia or involuntary movements in mid-to-late stage Parkinson's disease. The findings will ...

New therapeutic principle for Parkinsonian dyskinesia shows clinical effect

February 10, 2015
Involuntary dyskinetic movements induced by treatment with levodopa (L-dopa) are a common problem for people with Parkinson's disease. Now, however, researchers at Karolinska Institutet and Lund University in Sweden seem ...

Highest adverse effect rates for three drugs in parkinson's

September 21, 2017
(HealthDay)—Ropinirole, bromocriptine, and piribedil are associated with the highest incidence rates of adverse effects in Parkinson's disease, according to a review published online Sept. 4 in CNS Neuroscience & Therapeutics.

Recommended for you

New transgenic model of Parkinson's illuminates disease biology

October 11, 2018
Parkinson's disease (PD) is a neurodegenerative disorder that presents clinically with abnormal movement and tremors at rest. In the brain, PD is marked by the accumulation of the protein, α-synuclein (αS), into clumps ...

Early Parkinson's patients waiting too long to seek medical evaluation

September 27, 2018
The time between diagnosis and the institution of symptomatic treatment is critical in the effort to find a cure for Parkinson's Disease (PD). A paper published in Nature Partner Journal: Parkinson's Disease notes too many ...

Molecule capable of halting and reverting neurodegeneration caused by Parkinson's disease identified

September 25, 2018
The small SynuClean-D molecule interrupts the formation of the alpha-synuclein amyloid fibres responsible for the onset of Parkinson's disease, and reverts the neurodegeneration caused by the disease. The study, headed by ...

Genomic dark matter activity connects Parkinson's and psychiatric diseases

September 20, 2018
Dopamine neurons are located in the midbrain, but their tendril-like axons can branch far into the higher cortical areas, influencing how we move and how we feel. New genetic evidence has revealed that these specialized cells ...

Gene therapy shown to remove core component of Parkinson's disease

September 14, 2018
An international team led by Rush researcher Jeffrey Kordower, Ph.D., has moved a step closer to developing a treatment to clear brain cells of a protein that is an integral cause of Parkinson's disease. The team published ...

ADHD may increase risk of Parkinson's disease and similar disorders

September 12, 2018
While about 11 percent of children (4-17 years old) nationwide have been diagnosed with attention-deficit hyperactivity disorder (ADHD), the long-term health effects of having ADHD and of common ADHD medications remains understudied. ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.